Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors
Authors:
- Shannon S. WuSWShannon S. Wu
- Eric D. LamarreELEric D. Lamarre
- Joseph ScharpfJSJoseph Scharpf
- Brandon PrendesBPBrandon Prendes
- Jamie A. KuJKJamie A. Ku
- Natalie SilverNSNatalie Silver
- Brian BurkeyBBBrian Burkey
- Neil WoodyNWNeil Woody
- Shauna R. CampbellSCShauna R. Campbell
- Emrullah YilmazEYEmrullah Yilmaz
- Shlomo A. KoyfmanSKShlomo A. Koyfman
- Jessica GeigerJGJessica Geiger
- 18 August 2023
- journal article
- research article
- Published by Elsevier in Endocrine Practice
- Vol. 29 (11) , 881-889
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Brain Metastases from Thyroid Carcinoma: A Retrospective Study of 21 PatientsThyroid®, 2014
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid CancerNew England Journal of Medicine, 2013
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationJournal of Clinical Investigation, 2011
- Cytotoxic Chemotherapy for Differentiated Thyroid CarcinomaClinical Oncology, 2010
- Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancersJournal of Neuro-Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Chemotherapy with Doxorubicin in Progressive Medullary and Thyroid Carcinoma of the Follicular EpitheliumHormone and Metabolic Research, 2008
- Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcomeClinical Endocrinology, 2005
- Management of brain metastases from thyroid carcinomaCancer, 2003